Showing results (841-850 of 850) with videos related to
Sort By:
Pageof 85
You have reached the last page of results.This site can display upto 850 results.
Antiviral Research|March 5, 2023
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccineChangrui Lu, Yuntao Zhang, Xiaohu Liu, et al.Journal of Hepatology|December 21, 2020
Association of liver abnormalities with in-hospital mortality in patients with COVID-19Ze-Yang Ding, Gan-Xun Li, Lin Chen, et al.Scientific Data|March 28, 2019
Author Correction: Draft genomic and transcriptome resources for marine chelicerate Tachypleus tridentatusYong Yan Liao, Peng Wei Xu, Kit Yue Kwan, et al.Scientific Data|February 27, 2019
Draft genomic and transcriptome resources for marine chelicerate Tachypleus tridentatusYong Yan Liao, Peng Wei Xu, Kit Yue Kwan, et al.Primary Care Diabetes|January 28, 2023
Consensus of Chinese experts on strengthening personalized prevention and treatment of type 2 diabetesBin Lu, Jianqin Sun, Lili Chen, et al.Nature Communications|March 28, 2023
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2Brian C Sanders, Suman Pokhrel, Audrey D Labbe, et al.Acta Pharmacologica Sinica|July 27, 2022
A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture riskHao Zhang, Jie-Mei Gu, Ai-Jun Chao, et al.Nature Medicine|May 13, 2022
Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialDalong Zhu, Xiaoying Li, Jianhua Ma, et al.Diabetologia|November 21, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.Nature Medicine|May 13, 2022
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trialWenying Yang, Dalong Zhu, Shenglian Gan, et al.Pageof 85